Search
Otenabant
go.drugbank.com/drugs/DB11745InvestigationalOtenabant has been investigated for the treatment of Obesity.
Categories: Cannabinoid Receptor Antagonists, Receptor, Cannabinoid, CB1, antagonists & inhibitorsStem bromelain
go.drugbank.com/drugs/DB12249ApprovedThe primary therapeutic use for which stem bromelain is currently and formally indicated is as a burn wound eschar debridement agent that has been approved by the EMA since 2012 and marketed under the
Trofinetide
go.drugbank.com/drugs/DB06045Approved, making trofinetide the first and only treatment approved for Rett syndrome in the European Union. … [A258438] Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked neurodevelopmental disorder characterized by a range of cognitive
Estriol
go.drugbank.com/drugs/DB04573ApprovedInvestigationalVet approvedIt has also been approved and marketed throughout Europe and Asia for approximately 40 years for the treatment of post-menopausal hot flashes. … Though estriol is used as part of the primarily North American phenomenon of bioidentical hormone replacement therapy, it is not approved for use by the FDA or Health Canada.
Autologous cultured chondrocytes
go.drugbank.com/drugs/DB10997ApprovedInvestigationalIt serves as an alternative repair treatment for patients with inadequate response to pre-existing surgical methods. … The surgical implantation shows a tolerable safety profile and efficacy up to 4 years, but it is not indicated for patients with osteoarthritis.
Zinc dibutyldithiocarbamate
go.drugbank.com/drugs/DB14194ApprovedZinc dibutyldithiocarbamate is a dermatological sensitizer and allergen. Sensitivity to zinc dibutyldithiocarbamate may be identified with a clinical patch test.
Categories: Agents for Treatment of Hemorrhoids and Anal Fissures for Topical UseRevumenib
go.drugbank.com/drugs/DB18515ApprovedInvestigational[L51888] In October of 20225, it was approved for myeloid leukemia patients with nucleophosmin 1 (NPM1) mutations. [L54376] … It was approved by the FDA in November 2024 for the treatment of leukemia with KMT2A aberrations,[L51868,L51863] becoming the first menin inhibitor to receive FDA approval.
Sarafloxacin
go.drugbank.com/drugs/DB11491ApprovedVet approvedWithdrawnSarafloxacin is a quinolone antibiotic drug, which was discontinued by its manufacturer, Abbott Laboratories, before receiving approval for use in the US or Canada.
Finafloxacin
go.drugbank.com/drugs/DB09047ApprovedWithdrawnFinafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus. Finafloxacin is marketed by Novartis under the brand...
Raltegravir
go.drugbank.com/drugs/DB06817ApprovedInvestigationalRaltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase ...
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use